[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

October 2018 - April 2015

Decade

Year

Issue

November 2018, Vol 4, No. 11, Pages 1453-1626

Original Investigation

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast CancerA Life-Table Model

Abstract Full Text
open access has audio
JAMA Oncol. 2018;4(11):1504-1510. doi:10.1001/jamaoncol.2018.1901

This cost-effectiveness study uses a life-table model of a hypothetical cohort of 364 500 women to evaluate the cost-effectiveness and benefit to harm ratio of risk-stratified screening for breast cancer.

Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(11):1511-1516. doi:10.1001/jamaoncol.2018.1908

This survey study examines the propensity of surgeons to use axillary lymph node biopsy alone for axillary management in women with early-stage breast cancer undergoing breast-conserving surgery.

Defining Survivorship Trajectories Across Patients With Solid TumorsAn Evidence-Based Approach

Abstract Full Text
JAMA Oncol. 2018;4(11):1519-1526. doi:10.1001/jamaoncol.2018.2761

This cohort study uses Surveillance, Epidemiology, and End Results data to determine high- and low-risk periods for 68 cancer types that could define when survivorship care might best be overseen by oncologists and when to transition to primary care physicians.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Abstract Full Text
JAMA Oncol. 2018;4(11):1527-1534. doi:10.1001/jamaoncol.2018.2969

This cohort study examines mechanisms of acquired resistance to osimertinib in patients with non–small cell lung cancer and the associated clinical implications.

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer

Abstract Full Text
JAMA Oncol. 2018;4(11):1535-1542. doi:10.1001/jamaoncol.2018.3542

This cross-sectional analysis compares downstaging, responses, and survival outcomes in patients with muscle-invasive bladder cancer treated with cystectomy who underwent neoadjuvant chemotherapy with gemcitabine with cisplatin, gemcitabine with carboplatin, or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin.

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Abstract Full Text
has audio
JAMA Oncol. 2018;4(11):1543-1552. doi:10.1001/jamaoncol.2018.3676

This multicenter cohort study investigates whether hyperprogressive disease is observed in patients with advanced non–small cell lung cancer treated with programmed cell death 1 and programmed cell death ligand 1 inhibitors compared with single-agent chemotherapy.

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016A Systematic Analysis for the Global Burden of Disease Study

Abstract Full Text
open access
JAMA Oncol. 2018;4(11):1553-1568. doi:10.1001/jamaoncol.2018.2706

This systematic analysis evaluates the cancer burden over time at the global and national levels measured in incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years.

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerThe ALTER 0303 Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(11):1569-1575. doi:10.1001/jamaoncol.2018.3039

This randomized clinical trial examines the efficacy of anlotinib compared with placebo as a third-line or further therapy on overall survival of adult patients with advanced non–small cell lung cancer.

Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries

Abstract Full Text
JAMA Oncol. 2018;4(11):1576-1582. doi:10.1001/jamaoncol.2018.3054

This cohort study of patients from the 5 Nordic countries examines whether gastroesophageal antireflux surgery is associated with decreased risk of esophageal adenocarcinoma and whether surgically and medically treated patients experience different outcomes.

Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women

Abstract Full Text
open access online only
JAMA Oncol. 2018;4(11):e181771. doi:10.1001/jamaoncol.2018.1771

This pooled analysis of individual patient data investigates the association of body mass index with subsequent breast cancer risk, in particular by age, attained age, risk factors for breast cancer, and tumor characteristics, in premenopausal women.

Monthly High-Dose Vitamin D Supplementation and Cancer RiskA Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2018;4(11):e182178. doi:10.1001/jamaoncol.2018.2178

This post hoc analysis of the Vitamin D Assessment randomized clinical trial assesses the association of monthly high-dose vitamin D supplementation vs placebo on cancer risk among New Zealand adults.

Brief Report

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and NeckThe Active8 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(11):1583-1588. doi:10.1001/jamaoncol.2018.1888

This randomized clinical trial compares outcomes of standard chemotherapy and cetuximab combination therapy with vs without motolimod in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors

Abstract Full Text
JAMA Oncol. 2018;4(11):1589-1593. doi:10.1001/jamaoncol.2018.2297

This gene-sequencing study identifies and quantifies clonal hematopoiesis–related mutations in patients with solid-tumor cancers using matched tumor-blood sequencing and examines the proportion that would be misattributed to the tumor based on tumor-only sequencing (unmatched analysis).

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast CancerSecondary Analysis of the NeoALTTO Randomized Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2018;4(11):e181564. doi:10.1001/jamaoncol.2018.1564

This biomarker study estimates the diversity of T-cell populations in the tumor microenvironment by assessing messenger RNA expression of the T-cell receptor β chain variable gene from RNA sequencing data of pretreatment biopsies of women with HER2-positive breast cancer in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial.

Research Letter

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials

Abstract Full Text
JAMA Oncol. 2018;4(11):1610-1611. doi:10.1001/jamaoncol.2018.4300

This study uses the European Society of Medical Oncology Magnitude of Clinical Benefit Scale to evaluate the clinical benefit of anticancer drugs that gained approval by the US Food and Drug Administration based on single-arm rather than randomized clinical trials.

Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung Cancer

Abstract Full Text
JAMA Oncol. 2018;4(11):1611-1613. doi:10.1001/jamaoncol.2018.4387

This population-based study compares opioid use in patients with non–small cell lung cancer who underwent open resection vs video-assisted thoracoscopic surgery.

Erectile Dysfunction in Male Survivors of Childhood Cancer

Abstract Full Text
JAMA Oncol. 2018;4(11):1613-1616. doi:10.1001/jamaoncol.2018.4420

This survey study evaluates the presence of erectile dysfunction in men who had experienced cancer during childhood.

Association of Androgen Deprivation Therapy With Dementia in Men With Prostate Cancer Who Receive Definitive Radiation Therapy

Abstract Full Text
JAMA Oncol. 2018;4(11):1616-1617. doi:10.1001/jamaoncol.2018.4423

This cohort study examines the association of androgen deprivation therapy with dementia in male veterans with prostate cancer who receive definitive radiotherapy.

Special Communication

Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors

Abstract Full Text
JAMA Oncol. 2018;4(11):1597-1604. doi:10.1001/jamaoncol.2018.2428

This Special Communication discusses consensus recommendations regarding follow-up of fully resected, well-differentiated, or moderately differentiated gastroenteropancreatic neuroendocrine tumors.

JAMA Network Insights

Management of Liver Neuroendocrine Tumors in 2018

Abstract Full Text
JAMA Oncol. 2018;4(11):1605-1606. doi:10.1001/jamaoncol.2018.3035

This Insights discusses management strategies for liver neuroendocrine tumors using the most recent therapeutic options.

JAMA Oncology Clinical Challenge

A New Dark Skin Lesion in a 3-Year-Old Undergoing Induction Therapy for Acute Lymphoblastic Leukemia

Abstract Full Text
JAMA Oncol. 2018;4(11):1607-1608. doi:10.1001/jamaoncol.2018.2086

A 3-year-old girl with B-cell acute lymphoblastic leukemia and no known skin trauma presented with an asymptomatic skin lesion with violaceous to black plaque, a central hemorrhagic bulla, and surrounding hyperemia on the left lower back. What is your diagnosis?

Viewpoint

Unproven Efficacy of Low-Dose Bisphosphonates as a Means of Decreasing Bone Metastases and Death in Early Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(11):1477-1478. doi:10.1001/jamaoncol.2018.2674

This Viewpoint assesses the use of low-dose bisphosphonates to reduce the risks of bone metastases and mortality in postmenopausal patients with early breast cancer.

Engaging Patients in Value-Based Cancer CareA Missed Opportunity

Abstract Full Text
JAMA Oncol. 2018;4(11):1479-1480. doi:10.1001/jamaoncol.2018.2826

This Viewpoint examines how a more patient-focused payment model could improve the success of payment reforms that encourage higher-value care.

Orphan Cancer Drugs in the Era of Precision Medicine

Abstract Full Text
JAMA Oncol. 2018;4(11):1481-1482. doi:10.1001/jamaoncol.2018.3498

This Viewpoint discusses whether the changes in the health care marketplace, the evolution of precision medicine, and the uniqueness of drug development and labeling for cancer diagnoses make the Orphan Drug Act less necessary and less relevant today than at its inception.

Editorial

Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine

Abstract Full Text
JAMA Oncol. 2018;4(11):1484-1485. doi:10.1001/jamaoncol.2018.1940
Invited Commentary

Delayed Adoption of Evidence-Based Breast Cancer Surgical PracticesHistory Repeats Itself

Abstract Full Text
JAMA Oncol. 2018;4(11):1517-1518. doi:10.1001/jamaoncol.2018.1939
Cancer Care Chronicles

Terminal Cancer and Death—On Grief

Abstract Full Text
JAMA Oncol. 2018;4(11):1483. doi:10.1001/jamaoncol.2018.3883

This essay describes the process of coming to an understanding of grief following the death of a family member who had cancer.

Poetry and Oncology

Long Live Neutrophil

Abstract Full Text
JAMA Oncol. 2018;4(11):1626. doi:10.1001/jamaoncol.2018.4497
Comment & Response

Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma

Abstract Full Text
JAMA Oncol. 2018;4(11):1617-1618. doi:10.1001/jamaoncol.2018.3483

Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma—Reply

Abstract Full Text
JAMA Oncol. 2018;4(11):1618. doi:10.1001/jamaoncol.2018.3501

Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy

Abstract Full Text
JAMA Oncol. 2018;4(11):1618-1619. doi:10.1001/jamaoncol.2018.3533

Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy

Abstract Full Text
JAMA Oncol. 2018;4(11):1619-1620. doi:10.1001/jamaoncol.2018.3536

Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy

Abstract Full Text
JAMA Oncol. 2018;4(11):1620. doi:10.1001/jamaoncol.2018.3539

Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy—Reply

Abstract Full Text
JAMA Oncol. 2018;4(11):1620-1621. doi:10.1001/jamaoncol.2018.3552

Information Transparency in the Drug Approval Process

Abstract Full Text
JAMA Oncol. 2018;4(11):1621-1622. doi:10.1001/jamaoncol.2018.4143

Information Transparency in the Drug Approval Process—Reply

Abstract Full Text
JAMA Oncol. 2018;4(11):1622. doi:10.1001/jamaoncol.2018.4163

Oral Contraceptive Progestin and Estrogen Use and Increases in Breast, Ovarian, and Endometrial Cancers

Abstract Full Text
JAMA Oncol. 2018;4(11):1623. doi:10.1001/jamaoncol.2018.4146

Oral Contraceptive Progestin and Estrogen Use and Increases in Breast, Ovarian, and Endometrial Cancers—Reply

Abstract Full Text
JAMA Oncol. 2018;4(11):1623-1624. doi:10.1001/jamaoncol.2018.4166

Magnetic Resonance Imaging–Based Prediction of Prostate Cancer Risk

Abstract Full Text
JAMA Oncol. 2018;4(11):1624-1625. doi:10.1001/jamaoncol.2018.4221

Magnetic Resonance Imaging–Based Prediction of Prostate Cancer Risk—Reply

Abstract Full Text
JAMA Oncol. 2018;4(11):1625. doi:10.1001/jamaoncol.2018.4234
Correction

Errors in Number at Risk and Author Email Address

Abstract Full Text
free access
JAMA Oncol. 2018;4(11):1625. doi:10.1001/jamaoncol.2018.5345
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(11):1455. doi:10.1001/jamaoncol.2017.3258
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(11):1453. doi:10.1001/jamaoncol.2017.3257
×